BRPI0407734A - derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo - Google Patents

derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo

Info

Publication number
BRPI0407734A
BRPI0407734A BRPI0407734-2A BRPI0407734A BRPI0407734A BR PI0407734 A BRPI0407734 A BR PI0407734A BR PI0407734 A BRPI0407734 A BR PI0407734A BR PI0407734 A BRPI0407734 A BR PI0407734A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical compositions
processes
compositions containing
adamantane derivatives
Prior art date
Application number
BRPI0407734-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Moya Caffrey
Rhonan Ford
Austen Pimm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0407734A publication Critical patent/BRPI0407734A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
    • C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
    • C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0407734-2A 2003-02-21 2004-02-19 derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo BRPI0407734A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds
PCT/SE2004/000227 WO2004074224A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them

Publications (1)

Publication Number Publication Date
BRPI0407734A true BRPI0407734A (pt) 2006-02-14

Family

ID=20290476

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407734-2A BRPI0407734A (pt) 2003-02-21 2004-02-19 derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo

Country Status (18)

Country Link
US (1) US7227038B2 (enExample)
EP (1) EP1599432A1 (enExample)
JP (1) JP2006518376A (enExample)
KR (1) KR20050101559A (enExample)
CN (1) CN100378047C (enExample)
AU (1) AU2004213356B2 (enExample)
BR (1) BRPI0407734A (enExample)
CA (1) CA2515434A1 (enExample)
CO (1) CO5580815A2 (enExample)
IL (1) IL169818A0 (enExample)
IS (1) IS8024A (enExample)
MX (1) MXPA05008690A (enExample)
NO (1) NO20054329L (enExample)
PL (1) PL378574A1 (enExample)
RU (1) RU2005123802A (enExample)
SE (1) SE0300480D0 (enExample)
WO (1) WO2004074224A1 (enExample)
ZA (1) ZA200506579B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
JP2007501270A (ja) * 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
NZ547794A (en) 2003-12-18 2009-11-27 Janssen Pharmaceutica Nv Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
EP1906960A4 (en) * 2005-07-11 2010-03-10 Astrazeneca Ab NEW COMBINATION 1
EP2044084B1 (en) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
ES2380908T3 (es) 2009-04-14 2012-05-21 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su uso
EA201201548A1 (ru) 2010-05-14 2013-05-30 Эффектис Фармасьютиклз Аг Новые способы получения p2x7r антагонистов
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
RU2014106611A (ru) 2011-07-22 2015-08-27 Актелион Фармасьютиклз Лтд Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора
HK1203932A1 (en) 2012-01-20 2015-11-06 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
JP6423353B2 (ja) * 2012-11-09 2018-11-14 ハズ トゥー，エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
WO2014091415A1 (en) 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2014115078A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
EP0720601B1 (en) 1993-08-10 2000-10-25 James Black Foundation Limited Gastrin and cck receptor ligands
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6492355B1 (en) * 1999-04-09 2002-12-10 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
WO2003004028A1 (en) * 2001-07-02 2003-01-16 Akzo Nobel N.V. Tetrahydroquinoline derivatives
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) 2003-02-18 2003-02-18 Astrazeneca Ab New combination
JP2007501270A (ja) 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
US20070010497A1 (en) 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
US20060160904A1 (en) 2006-07-20
IL169818A0 (en) 2007-07-04
SE0300480D0 (sv) 2003-02-21
AU2004213356A1 (en) 2004-09-02
EP1599432A1 (en) 2005-11-30
JP2006518376A (ja) 2006-08-10
CN100378047C (zh) 2008-04-02
WO2004074224A1 (en) 2004-09-02
US7227038B2 (en) 2007-06-05
NO20054329D0 (no) 2005-09-20
CO5580815A2 (es) 2005-11-30
ZA200506579B (en) 2006-05-31
AU2004213356B2 (en) 2007-03-15
PL378574A1 (pl) 2006-05-02
MXPA05008690A (es) 2005-10-05
RU2005123802A (ru) 2006-02-27
CA2515434A1 (en) 2004-09-02
IS8024A (is) 2005-09-14
KR20050101559A (ko) 2005-10-24
NO20054329L (no) 2005-11-21
CN1751010A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0111667A (pt) Novos compostos
BR0108678A (pt) Novos compostos
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
SE9904505D0 (sv) Novel compounds
BR0208338A (pt) Derivados de piridina
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0410933A (pt) novos antagonistas do receptor p2x7 e seu uso
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BR0312464A (pt) Inibidores de tirosina quinases
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BR0309242A (pt) Derivados de acil-4-carboxifenil-uréia, processo para a sua preparação e sua aplicação
BR0214142A (pt) Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR9712816A (pt) Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BR9909739A (pt) Benzotiadiazóis e derivados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.